Why Oracle Stock Zoomed Nearly 13% Higher This Week
It provided a somewhat offbeat yet compelling business update.
It's also reportedly doing a sizable deal with a top name in artificial intelligence.
Over the past few days, many investors gazed into the future of database king Oracle (NYSE: ORCL) and liked what they saw.
On the back of positive remarks from the company's CEO and bolstered by an apparent deal with a major artificial intelligence (AI) developer, the stock's price resolutely headed north. According to data compiled by S&P Global Market Intelligence, it rose by just under 13% during the week.
Two hot business segments
Oracle's fine week kicked off on Monday, when the company provided an update about an important business segment. Somewhat oddly, this was done with a regulatory filing framed by a quote attributed to CEO Safra Catz.
According to the company, in a planned meeting with colleagues later that day, she was to say: "Oracle is off to a strong start in fiscal year 2026. Our MultiCloud database revenue continues to grow at over 100%, and we signed multiple large cloud services agreements including one that is expected to contribute more than $30 billion in annual revenue starting in fiscal year 2028."
Oracle did not provide more details, either in the regulatory filing or in subsequent communications.
Several days later, a report published in Bloomberg said that OpenAI -- the developer of ChatGPT -- agreed to lease significant space in Oracle data centers. The financial news agency cited unnamed "people familiar with the work," as saying that OpenAI aims to rent additional capacity of roughly 4.5 gigawatts of data center power in this country.
The move is aimed at further advancing the Stargate Project, the AI partnership of Oracle, OpenAI, and tech investment enterprises SoftBank and MGX.
Cloudy days in the summer
With the rather vague, two-sentence update from Catz we can't make a highly educated guess as to how MultiCloud's wins will affect the company. That said, the stated growth rate for the business and the news about the latest contracts sounds as if it's firing on all cylinders. And although the OpenAI report is so far unconfirmed by Oracle, it also sounds like a potential money-spinner for the company.
Should you invest $1,000 in Oracle right now?
Before you buy stock in Oracle, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Oracle wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!*
Now, it's worth noting Stock Advisor 's total average return is1,060% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 30, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
9 minutes ago
- Globe and Mail
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry 's decline of 2.2%. The stock has also outperformed the sector and the S&P 500 index in this time frame. Gilead Outperforms Industry, Sector & S&P 500 Index It has been an eventful year for GILD so far. The company recently obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. This groundbreaking injectable therapy marks the first and only twice-yearly pre-exposure prophylaxis (PrEP) option available in the United States. Let's delve further into GILD's strengths and weaknesses to analyze how to play the stock at present. Lenacapavir Approval Boosts GILD's HIV Franchise Gilead has a market-leading portfolio of HIV treatments. Flagship drug Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum. Descovy (FTC 200 mg/TAF 25 mg) for PrEP is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States. The recent FDA approval of lenacapavir under the brand name Yeztugo solidifies GILD's HIV portfolio as its other prevention drug, Truvada, faces generic competition. At present, there are two FDA-approved daily oral medications for PrEP — Truvada and Descovy. As the first long-acting injectable PrEP administered just twice a year, Yeztugo addresses persistent barriers, such as challenges with daily oral PrEP, adherence, stigma and healthcare access, which have limited broader PrEP adoption. This approval also represents a paradigm shift in HIV prevention and is expected to catalyze uptake among populations that have historically been underserved by existing prevention tools. Yeztugo has a competitive advantage as it needs to be taken only twice a year, unlike daily oral pills, and addresses a broad population. The European Medicines Agency has also validated the Marketing Authorization Application for twice-yearly lenacapavir for HIV prevention. Livdelzi Strengthens GILD's Liver Disease Portfolio GILD's diverse portfolio also includes drugs for liver, hematology/oncology and inflammation/respiratory diseases. The FDA approval of seladelpar for the treatment of primary biliary cholangitis (PBC) has strengthened GILD's liver disease portfolio and validated its CymaBay acquisition. The drug's initial uptake is encouraging. The candidate was approved under the brand name Livdelzi. Gilead also recently received conditional marketing authorization from the European Commission for seladelpar for the treatment of PBC. Challenges for GILD's Oncology Business Gilead's oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue in 2025. Breast cancer drug Trodelvy's sales were lower than expected in the first quarter due to inventory dynamics. Nonetheless, Gilead announced positive top-line results from the phase III ASCENT-03 study on Trodelvy, which showed highly statistically significant and clinically meaningful improvement in progression-free survival in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for checkpoint inhibitors. The potential launch of anito-cel in multiple myeloma and Trodelvy in first-line mTNBC in 2026 will strengthen the company's oncology business. GILD's Valuation and Estimate Revision According to the price/earnings ratio, GILD's shares currently trade at 13.62x forward earnings, lower than the large-cap pharma industry's average of 15.01X but higher than its mean of 10.52X. Earnings estimates for GILD have moved north in the past 60 days. The bottom-line estimate for 2025 has inched up to $7.92 from $7.91, while that for 2026 has improved to $8.48 from $8.39. Invest in GILD Large biotech companies are generally considered safe havens for investors interested in this sector as they are well-equipped to weather the uncertain macroenvironment. Gilead's efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc GSK. The approval of Yeztugo for PrEP is a major boost for the company. GSK's HIV portfolio sales are being driven by strong patient demand for Cabenuva, Apretude and Dovato. GILD has also collaborated with Merck MRK to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. Gilead's strategic deals and acquisitions to diversify its business are encouraging. We recommend the stock to prospective investors, as we believe there is more room for growth following Yeztugo approval, even though Biktarvy sales are expected to be under pressure due to the redesign of Medicare Part D. Another positive factor for both prospective and existing investors is the company's attractive dividend yield. Gilead has been consistently increasing and paying out dividends. The company declared a quarterly dividend of $0.79 per share of common stock for the second quarter of 2025. Its strong cash position (as of March 31, 2025, GILD had $7.9 billion of cash, cash equivalents and marketable debt securities) indicates that the current yield of 2.83% is sustainable. Gilead presently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Globe and Mail
24 minutes ago
- Globe and Mail
Cal-Maine Foods, Inc. Announces Release Date for Fourth Quarter and Fiscal 2025 Results
Cal-Maine Foods, Inc. (NASDAQ: CALM) today announced that the Company will release its fourth quarter and fiscal 2025 financial results on Tuesday, July 22, 2025. A press release will be issued after the close of market trading. About Cal-Maine Foods Cal-Maine Foods, Inc. is primarily engaged in the production, packaging, marketing and distribution of fresh shell eggs, including conventional, cage-free, organic, brown, free-range, pasture-raised and nutritionally enhanced eggs, as well as a variety of egg products and prepared foods. The Company, which is headquartered in Ridgeland, Mississippi, is the largest producer and distributor of fresh shell eggs in the nation and sells most of its shell eggs throughout the majority of the United States.
Globe and Mail
25 minutes ago
- Globe and Mail
5 ETFs to Profit From Amazon's Longest-Ever Prime Day Event
Online e-commerce behemoth Amazon AMZN has kicked off its most anticipated and longest-ever Prime Day event. The event has expanded from 48 to 96 hours this year, running from July 8 to 11. Adobe predicts the four-day shopping spree will equal the combined online spending of two Black Fridays. U.S. online sales are expected to soar to a record $23.8 billion during Amazon's four-day Prime Day sales event, according to Adobe. The surge in spending marks a 28.4% year-over-year increase, as consumers hunt for deep discounts on back-to-school essentials, from clothing and electronics to backpacks and college gear. The four-day spending over the event is expected to be equivalent to two Black Fridays, in terms of online spending (read: 5 ETF Predictions for the Second Half of 2025). Investors can tap the opportune moment with ETFs having a double-digit allocation to this online behemoth. These include ProShares Online Retail ETF ONLN, Fidelity MSCI Consumer Discretionary Index ETF FDIS, Vanguard Consumer Discretionary ETF VCR, Consumer Discretionary Select Sector SPDR Fund XLY and VanEck Vectors Retail ETF RTH. New Tactics: Deal Drops & Mobile Spending The e-commerce technology giant has been promising millions of discounts on products across its e-commerce platform during the four-day event. It has introduced daily deal drops (limited-time offers) that encourage consumers to check back frequently. Mobile shopping is expected to play a central role, with purchases from smartphones and tablets projected to reach $12.5 billion, or 52.5% of total sales. Adobe noted that mobile users tend to make more impulse purchases, making this channel a key driver of growth. Deep Discounts Across Categories Adobe expects Prime Day discounts to match last year's levels, with the most attractive deals in apparel at 24%, followed by electronics 22% off, TVs 17% off, appliances 16% off, toys 15%, furniture 14%, computers 12%, and sporting goods 10% (read: 4 ETF Areas to Win Amid Slowing Retail Sales in May). AI Tools to Gather Traction Generative AI-powered shopping assistants and chatbots are poised to play a bigger role this year. Adobe expects traffic from AI sources to surge by 3,200% compared to last year's Prime Day, building on trends seen during the 2024 holiday season. 'While AI-driven traffic remains small relative to channels like paid search or email, the growth illustrates the value consumers see in using AI for product discovery and deal-hunting,' Adobe noted. Buy Now, Pay Later (BNPL) Traffic to Rise Adobe also forecasts a bump in BNPL usage, which is projected to account for 8% of overall online sales during the event, up from 7.6% in 2024. ETFs in Focus ProShares Online Retail ETF (ONLN) ProShares Online Retail ETF offers exposure to companies that principally sell online or through other non-store channels and then zeroes in on the companies that reshape the retail space. It tracks the ProShares Online Retail Index, holding 20 stocks in its basket. Amazon is the top firm, accounting for 24.5% of the portfolio. ProShares Online Retail ETF has amassed $78.3 million in its asset base and charges 58 bps in annual fees from investors. Fidelity MSCI Consumer Discretionary Index ETF (FDIS) Fidelity MSCI Consumer Discretionary Index ETF tracks the MSCI USA IMI Consumer Discretionary Index, holding 259 stocks in its basket. Of these, Amazon takes the top spot with a 24.2% share. Fidelity MSCI Consumer Discretionary Index ETF has amassed $1.8 billion in its asset base and charges 8 bps in annual fees from investors. It has a Zacks ETF Rank #4 (Sell) with a Medium risk outlook. Vanguard Consumer Discretionary ETF (VCR) Vanguard Consumer Discretionary ETF currently follows the MSCI US Investable Market Consumer Discretionary 25/50 Index and holds 296 stocks in its basket. Of these, Amazon occupies the top position, with a 22.8% allocation. Broadline Retail takes the largest share at 25.6%, while automobile manufacturers, restaurants, and home, resorts and cruise lines round off the next three spots. VCR charges investors 9 bps in annual fees. The product has managed $6.1 billion in its asset base and carries a Zacks ETF Rank #3 (Hold) with a Medium risk outlook (read: Will Tesla's Worst-Ever Q2 Vehicle Sales Drop Shake its ETFs?). Consumer Discretionary Select Sector SPDR Fund (XLY) Consumer Discretionary Select Sector SPDR Fund offers exposure to the broad consumer discretionary space by tracking the Consumer Discretionary Select Sector Index. It is the largest and the most popular product in this space, with AUM of nearly $22.8 billion. Holding 51 securities in its basket, Amazon takes the top spot with 23.3% of assets. Hotels, restaurants & leisure, broadline retail, specialty retail, and automobiles are the top four sectors with double-digit exposure each. Consumer Discretionary Select Sector SPDR Fund charges 0.08% in expense ratio and has a Zacks ETF Rank #3 with a Medium risk outlook. VanEck Vectors Retail ETF (RTH) VanEck Vectors Retail ETF provides exposure to the 26 largest retail firms by tracking the MVIS US Listed Retail 25 Index, which measures the performance of the companies involved in retail distribution, wholesalers, online, direct mail and TV retailers, multi-line retailers, specialty retailers and food and other staples retailers. Amazon takes the top position in the basket with a 20.4% share. VanEck Vectors Retail ETF has amassed $246.6 million in its asset base and charges 35 bps in annual fees. It has a Zacks ETF Rank #3 with a Medium risk outlook. Want key ETF info delivered straight to your inbox? Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report VanEck Retail ETF (RTH): ETF Research Reports ProShares Online Retail ETF (ONLN): ETF Research Reports
